Moxifloxacin vs Norfloxacin

## Overview

Moxifloxacin and norfloxacin represent the widest generational gap in the fluoroquinolone class. Moxifloxacin is a fourth-generation agent with broad anaerobic, gram-positive, gram-negative, and intracellular coverage. Norfloxacin is restricted to urinary/GI use.

## Mechanism of Action

Both inhibit DNA gyrase and topoisomerase IV. Moxifloxacin's C8-methoxy group and enhanced potency differentiate it fundamentally from norfloxacin.

## Clinical Relevance

This comparison is largely academic — there is no clinical scenario where these two drugs would be interchangeably considered. Moxifloxacin is used for CAP and anaerobic infections; norfloxacin for uncomplicated UTI. Neither has direct overlap in indications.

## Key Takeaways

- Moxifloxacin: broad-spectrum systemic (CAP, intra-abdominal); cannot treat UTI (poor urinary levels)
- Norfloxacin: narrow-spectrum systemic (UTI/GI only); obsolete where broader FQs available
- Completely different clinical niches